NeoGenomics (NEO) Stock Price, News & Analysis

Company Overview

NeoGenomics, Inc. is a provider of cancer-focused diagnostic testing and contract research services. The company operates clinical laboratories that support physicians, hospitals and other healthcare organizations with information used to help diagnose, classify and monitor cancer.

Its testing services include anatomic pathology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization, molecular testing and next-generation sequencing. NeoGenomics also provides biopharmaceutical companies with clinical trial testing, central laboratory services, biomarker development and other research services intended to support the development of oncology therapies and companion diagnostics.

Founded in 1999, NeoGenomics serves healthcare providers and pharmaceutical and biotechnology customers primarily in the United States, with additional capabilities supporting international clinical research programs. The company is headquartered in Fort Myers, Florida, and has expanded its laboratory and service network through organic growth and acquisitions. Chris Smith serves as the company's president and chief executive officer.

Key Stats

• Today's Range: $17.21 to $17.92
• 50-Day Range: $13.14 to $18.64
• 52-Week Range: $7.07 to $19.76
• Volume: 1.07 million shs
• Average Volume: 1.53 million shs
• Market Capitalization: $2.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.67
• Consensus Rating: Moderate Buy

NeoGenomics Stock Analysis - MarketRank™

NeoGenomics scored higher than 36% of companies evaluated by MarketBeat, and ranked 746th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 1 strong buy rating, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for NeoGenomics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

NeoGenomics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeoGenomics are expected to grow in the coming year, from ($0.09) to $0.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeoGenomics is -43.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeoGenomics is -43.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeoGenomics has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.40% of the float of NeoGenomics has been sold short.

Short Interest Ratio / Days to Cover

NeoGenomics has a short interest ratio ("days to cover") of 8.98.

Change versus previous month

Short interest in NeoGenomics has recently decreased by 0.75%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeoGenomics does not currently pay a dividend.

Dividend Growth

NeoGenomics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.19

News Sentiment

NeoGenomics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for NeoGenomics this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

7 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeoGenomics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.10% of the stock of NeoGenomics is held by insiders.

Percentage Held by Institutions

98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 9/12/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:NEO
• CIK: 1077183
• Web: www.neogenomics.com
• Phone: (239) 768-0600
• Fax: 239-690-4237
• Employees: 2,500
• Year Founded: 2002

Price Target and Rating

• Average Price Target for NeoGenomics: $17.67
• High Price Target: $25.00
• Low Price Target: $13.00
• Potential Upside/Downside: +2.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$108.03 million
• Net Margins: -6.77%
• Pretax Margin: -7.12%
• Return on Equity: -1.99%
• Return on Assets: -1.21%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 3.60
• Quick Ratio: 3.35

Sales & Book Value

• Annual Sales: $727.33 million
• Price / Sales: 3.06
• Cash Flow: $0.33 per share
• Price / Cash Flow: 52.56
• Book Value: $6.47 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 128,480,000
• Free Float: 127,062,000
• Market Cap: $2.23 billion
• Optionable: Optionable
• Beta: 1.75